Physician profile
Zuma Speakman
NPI 1639664519
$1,510.90
in general payments reported to CMS, 2019-2025
20 companies · $918 in 2025
The $918 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36.54 · 2023: $172 · 2024: $385 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $397.22 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $180.44 | 2024-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $114.74 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $106.35 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $105.75 | 2023-2025 | Jardiance, Mounjaro |
| Abbvie INC. | $85.35 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.57 | 2025 | |
| Shield Therapeutics INC | $63.84 | 2023-2025 | Accrufer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.67 | 2023-2025 | Jardiance |
| Dexcom, INC. | $63.26 | 2024-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $45.82 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Exact Sciences Corporation | $40.92 | 2023-2024 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $39.58 | 2023-2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $36.54 | 2019 | |
| Verona Pharma, INC. | $23.11 | 2025 | Ohtuvayre |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.44 | 2025 | Caplyta |
| Corcept Therapeutics | $15.60 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.24 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $13.76 | 2024 | Voquezna |
| Astellas Pharma US INC | $12.70 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zuma Speakman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.